Real World Clinical Outcomes for Metastatic Non-Small Cell Lung Cancer (mNSCLC) at IRST Italy

被引：0
|
作者：
Altini, M. [1 ]
Massa, I. [1 ]
Balzi, W. [1 ]
Gentili, N. [1 ]
Foca, F. [1 ]
Danesi, V. [1 ]
Manunta, S. [1 ]
Ejzykowicz, F. [2 ]
Chandwani, S. [3 ]
Burgio, M. [1 ]
Cravero, P. [1 ]
Verlicchi, A. [1 ]
Bronte, G. [1 ]
Crino, L. [1 ]
Delmonte, A. [1 ]
机构：
[1] IRCCS, Ist Sci Romagnolo Studio & Cura Tumor Irst, Meldola, Italy
[2] Merck & Co Inc, Oncol Prod Line, Core, Kenilworth, NJ USA
[3] Merck & Co Inc, Ctr Observat & Real World Evidence, Kenilworth, NJ USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
treatment pattern; real-world study; Outcomes;
D O I：
10.1016/j.jtho.2019.08.2369
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP1.16-04
引用
收藏
页码：S1065 / S1066
页数：2
相关论文
共 50 条
  • [21] Body composition as predictor of toxicity and outcomes in patients with metastatic non-small cell lung cancer (mNSCLC) receiving nivolumab (Nivo).
    Shachar, Shlomit Strulov
    Fried, Rachel
    Shafran, Itamar
    Moskovitz, Mor Tal
    Williams, Grant Richard
    Bar-Sela, Gil
    Reiner-Benaim, Anat Strulov
    Wollner, Mira
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [22] Outcomes with chemotherapy for metastatic non-small cell lung cancer (mNSCLC) in patients previously treated with immune checkpoint inhibitors (CPI).
    Elnair, Radowan
    Chang, Guy Vin
    Powell, Steven Francis
    Sumey, Christopher Joseph
    Bleeker, Jonathan Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [23] REAL-WORLD HEALTHCARE COSTS IN PATIENTS WITH METASTATIC NON SMALL CELL LUNG CANCER IN ITALY
    Danesi, V
    Massa, I
    Altini, M.
    Balzi, W.
    Gentili, N.
    Foca, F.
    Manunta, S.
    Ejzykowicz, F.
    Delmonte, A.
    VALUE IN HEALTH, 2019, 22 : S451 - S451
  • [24] Clinical predictors of prolonged clinical benefit (PCB) from pemetrexed (P) therapy in metastatic non-small cell lung cancer (mNSCLC)
    Sadraei, N. Hashemi
    Jones, C.
    Tan, A.
    Elson, P.
    Mekhail, T.
    Pennell, N. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [25] Disadvantaged subgroups of metastatic non-small cell lung cancer (mNSCLC) patients treated with nivolumab.
    Rossi, Sabrina
    Finocchiaro, Giovanna
    Toschi, Luca
    Santoro, Armando
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [26] Predictors of biomarker testing among patients (pts) with metastatic non-small cell lung cancer (mNSCLC).
    Robert, Nicholas J.
    Chen, Liwei
    Espirito, Janet L.
    Karhade, Mandar
    Evangelist, Makenzi Colleen
    Neubauer, Marcus A.
    Bullock, Susie A.
    Walberg, Jennifer M.
    Coleman, Robert L.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [27] COST OF IMMUNOTHERAPY TO TREAT LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER (MUC) AND METASTATIC NON-SMALL CELL LUNG CANCER (MNSCLC)
    Bilir, S. P.
    Munakata, J.
    Yim, Y. M.
    Ogale, S.
    VALUE IN HEALTH, 2017, 20 (05) : A99 - A99
  • [28] Real-world utilization of liquid biopsy for epidermal growth factor receptor (EGFR) testing in patients with metastatic non-small cell lung cancer (mNSCLC)
    Shah, Anne
    Apple, Jon
    Ryan, Debra L.
    de Silva, Kevin
    Cai, Ling
    Shenolikar, Rahul
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (28) : 402 - 402
  • [29] PREDICTORS OF EPIDERMAL GROWTH FACTOR (EGFR) TESTING AMONG PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (MNSCLC) TREATED IN THE REAL-WORLD SETTING
    Vasudevan, A.
    Sura, T.
    English, S.
    Wang, B.
    Varughese, P.
    Katzen, H.
    VALUE IN HEALTH, 2023, 26 (06) : S218 - S218
  • [30] Real World Experience of Nivolumab in Patients with Metastatic Nonsmall Cell Lung Cancer (mNSCLC)
    Ksienski, D.
    Wai, E.
    Lesperance, M.
    Croteau, N.
    Fiorino, L.
    Poonja, Z.
    Geller, G.
    Fenton, D.
    Brooks, E.
    Glick, D.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S480 - S480
12345